Compare OPRX & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPRX | DERM |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 258.2M | 210.0M |
| IPO Year | N/A | 2021 |
| Metric | OPRX | DERM |
|---|---|---|
| Price | $12.18 | $8.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $19.67 | $12.67 |
| AVG Volume (30 Days) | ★ 241.3K | 129.3K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $109,506,000.00 | $59,399,000.00 |
| Revenue This Year | $19.77 | $17.48 |
| Revenue Next Year | $11.33 | $55.83 |
| P/E Ratio | $6,661.29 | ★ N/A |
| Revenue Growth | ★ 24.18 | 2.82 |
| 52 Week Low | $3.99 | $3.54 |
| 52 Week High | $22.25 | $9.40 |
| Indicator | OPRX | DERM |
|---|---|---|
| Relative Strength Index (RSI) | 39.13 | 53.99 |
| Support Level | $12.23 | $7.15 |
| Resistance Level | $13.00 | $8.40 |
| Average True Range (ATR) | 0.79 | 0.41 |
| MACD | 0.04 | 0.08 |
| Stochastic Oscillator | 16.39 | 72.03 |
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.